Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy von Elias, D, Vever, H, Lænkholm, A-V, Gjerstorff, M F, Yde, C W, Lykkesfeldt, A E, Ditzel, H J

Volltext

Rates of re‐excision and conversion to mastectomy after breast‐conserving surgery with or without oncoplastic surgery: a nationwide population‐based study von Heeg, E., Jensen, M. B., Hölmich, L. R., Bodilsen, A., Tollenaar, R. A. E. M., Lænkholm, A. V., Offersen, B. V., Ejlertsen, B., Mureau, M. A. M., Christiansen, P. M.

Volltext

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy von Elias, D., Vever, H., Lænkholm, A.-V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., Ditzel, H. J.

Volltext

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells von Thrane, S, Pedersen, A M, Thomsen, M B H, Kirkegaard, T, Rasmussen, B B, Duun-Henriksen, A K, Lænkholm, A V, Bak, M, Lykkesfeldt, A E, Yde, C W

Volltext

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy von Elias, D., Vever, H., Lænkholm, A.-V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., Ditzel, H. J.

Volltext

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab von Jensen, J.D., Knoop, A., Laenkholm, A.V., Grauslund, M., Jensen, M.B., Santoni-Rugiu, E., Andersson, M., Ewertz, M.

Volltext

Breast cancer after bilateral risk-reducing mastectomy von Skytte, A-B, Crüger, D, Gerster, M, Lænkholm, A-V, Lang, C, Brøndum-Nielsen, K, Andersen, MK, Sunde, L, Kølvraa, S, Gerdes, A-M

Volltext

OP0026 Gene expression profiling identifies FYN as important in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy von Elias, D, Hansen, H, Lænkholm, A.-V, Gjerstorff, M.F, Yde, C.W, Lykkesfeldt, A.E, Ditzel, H.J

Volltext

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer von Knoop, A, Andreasen, PA, Andersen, JA, Hansen, S, Lænkholm, A-V, Simonsen, ACW, Andersen, J, Overgaard, J, Rose, C

Volltext

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients von Hansen, S, Overgaard, J, Rose, C, Knoop, Ann, Lænkholm, A-V, Andersen, J, Sørensen, F B, Andreasen, P A

Volltext

24P Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer clinicians: The PROCURE project von Curigliano, G., Cardoso, F., Gnant, M.I., Harbeck, N., Lænkholm, A-V., Penault-Llorca, F., Prat, A.

Volltext

Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer von Sønderstrup, I. M. H., Jensen, M. B., Ejlertsen, B., Eriksen, J. O., Gerdes, A. M., Kruse, T. A., Larsen, M. J., Thomassen, M., Laenkholm, A. V.

Volltext

P239 - Prognostic and predictive impact of estrogen receptor alpha gene (ESR1) expression in postmenopausal women with early breast cancer: Results from the DBCG 77C trial von Nielsen, S.S., Ejlertsen, B., Jensen, M.-B., Knoop, A., Lænkholm, A.-V.

Volltext

Prognostic and predictive impact of estrogen receptor alpha gene (ESR1) expression in postmenopausal women with early breast cancer: Results from the DBCG 77C trial von Nielsen, S.S., Ejlertsen, B., Jensen, M.-B., Knoop, A., Lænkholm, A.-V.

Volltext

Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG von Soenderstrup, I M H, Laenkholm, A V, Jensen, M B, Eriksen, J O, Gerdes, A M, Hansen, T V O, Kruse, T A, Larsen, M J, Pedersen, I S, Rossing, M, Thomassen, M, Ejlertsen, B

Volltext

Abstract P6-02-11: When needles are needed von von Euler-Chelpin, M, Vejborg, I, Lænkholm, A-V, Guleria, S, Peterkin, A, Lynge, E

Volltext

Abstract P2-10-02: Basal biomarkers nestin and INPP4b predict gemcitabine benefit in metastatic breast cancer: Results from the phase III SBG0102 clinical trial von Asleh-Aburaya, K, Lyck Carstensen, S, Burugu, S, Gao, D, Tykjær Jørgensen, CL, Won, JR, Jensen, M-B, Balslev, E, Lænkholm, A-V, Nielsen, DL, Ejlertsen, B, Nielsen, TO

Volltext

Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration von Nielsen, TO, Leung, SCY, Zabaglo, LA, Arun, I, Badve, SS, Bane, AL, Bartlet, JMS, Borgquist, S, Chang, MC, Dodson, A, Ehinger, A, Fineberg, S, Focke, CM, Gao, D, Gown, AM, Gutierrez, C, Hugh, JC, Kos, Z, Lænkholm, A-V, Mastropasqua, MG, Moriya, T, Nofech-Mozes, S, Osborne, CK, Penault-Llorca, FM, Piper, T, Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, van der Vegt, B, Viale, G, Hayes, DF, McShane, LM, Dowsett, M

Volltext

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type I in breast cancer patients von HANSEN, S, OVERGAARD, J, ROSE, C, KNOOP, Ann, LAENKHOLM, A-V, ANDERSEN, J, SØRENSEN, F. B, ANDREASEN, P. A

Volltext

Abstract P1-13-03: ER, PR, HER2, and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial von Knoop, AS, Lænkholm, A-V, Jensen, M-B, Nielsen, KV, Andersen, J, Nielsen, D, Ejlertsen, B

Volltext